Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,471 across all filing types
Latest filing 2022-01-18 Capital/Financing Update
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
ANNOUNCEMENT - INSIDE INFORMATION - ASCLETIS ANNOUNCES SIGNING OF RITONAVIR TABLET PURCHASE AGREEMENT WITH PHOKAM PHARMACEUTICAL IMPORT-EXPORT CO., LTD OF LAOS
Capital/Financing Update Classification · 90% confidence The document is an announcement by Ascletis Pharma Inc. regarding the signing of a purchase agreement for ritonavir tablets. It references compliance with the Listing Rules of the Hong Kong Stock Exchange and the Inside Information Provisions under the Securities and Futures Ordinance. The content focuses on a specific commercial agreement and provides background on the product and company plans. The document is relatively short (3166 characters) and does not contain financial statements, detailed financial analysis, or regulatory certifications. It is an announcement of a material contract or commercial transaction rather than a financial report or regulatory filing. This fits best under the category of Capital/Financing Update (CAP), as it relates to a significant commercial agreement impacting the company's business and potentially its capital or revenue streams. It is not a full financial report, management change, or legal proceeding. Therefore, the appropriate classification is CAP with high confidence.
2022-01-18 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks for Ascletis Pharma Inc. It references specific listing rules from the Stock Exchange of Hong Kong (SEHK) and details repurchase and cancellation of shares, including dates and quantities. The content is regulatory in nature, reporting share capital changes and compliance confirmations by the company secretary. It does not contain financial statements, earnings data, or management discussion. It is a formal disclosure of share capital changes, fitting the category of Share Issue/Capital Change announcements rather than a full financial report or other categories.
2022-01-17 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES U.S. IND APPROVAL OF ASC22 (ENVAFOLIMAB), A SUBCUTANEOUSLY ADMINISTERED PD-L1 ANTIBODY FOR FUNCTIONAL CURE OF CHRONIC HEPATITIS B
Capital/Financing Update Classification · 90% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the U.S. FDA approval of an Investigational New Drug (IND) application for ASC22 (Envafolimab), a drug candidate for chronic hepatitis B. It includes clinical trial interim results and licensing information. The document is an announcement of a regulatory milestone and clinical development update, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. It is also not a report publication announcement since it is a substantive announcement itself. The content fits best under Capital/Financing Update (CAP) as it relates to drug development progress and regulatory approval, which are material to the company's capital and financing outlook and investor information. Therefore, the classification is CAP with high confidence.
2022-01-17 English
DISCLOSEABLE TRANSACTION IN RELATION OF THE LEASE AGREEMENT
Regulatory Filings Classification · 95% confidence The document is an announcement by World Houseware (Holdings) Limited regarding a lease agreement entered into by its subsidiary Nam Sok Co. The announcement details the terms of the lease, the parties involved, the financial implications under HKFRS 16, and the listing rules implications. It explicitly states that the transaction constitutes a discloseable transaction under Chapter 14 of the Listing Rules and is subject to notification and announcement requirements. The document is not a full financial report, audit report, or earnings release, but rather a regulatory announcement about a material transaction (a lease agreement) that affects the company's assets and operations. It fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about a discloseable transaction that does not fall under more specific categories like capital update or M&A activity. The document length is about 12,000 characters, which is consistent with a detailed announcement rather than a brief notice or a full report.
2022-01-14 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES FIRST PATIENT DOSED IN THE PHASE II CLINICAL TRIAL OF FASN INHIBITOR ASC40 FOR TREATMENT OF MODERATE TO SEVERE ACNE
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the dosing of the first patient in a Phase II clinical trial for a drug candidate (ASC40). It contains no financial data, no regulatory certifications, no voting results, no management changes, no financial results, and no detailed report or presentation. The document is relatively short (3484 characters) and is an announcement of a clinical trial milestone rather than a financial or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a corporate announcement about a clinical trial progress, which is best classified under Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2022-01-13 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES FIRST PATIENT DOSED IN THE PHASE II CLINICAL TRIAL OF ASC42, AN IN-HOUSE DEVELOPED, BEST-IN-CLASS FXR AGONIST FOR CHRONIC HEPATITIS B INDICATION
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the dosing of the first patient in a Phase II clinical trial for a drug candidate ASC42. It contains no financial data, no regulatory certifications, no voting results, no management changes, no financial results, and no detailed report or presentation. The document is relatively short (3846 characters) and serves as a news update about clinical trial progress rather than a formal financial or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is an announcement of a clinical trial milestone, which is best categorized under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-01-11 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.